ProMetic Receives a $5.6 Million Purchase Order from Octapharma
June 05 2014 - 8:01AM
Marketwired
ProMetic Receives a $5.6 Million Purchase Order from Octapharma
LAVAL, QUEBEC--(Marketwired - Jun 5, 2014) - ProMetic Life
Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today that it has received a $5.6 million
purchase order under its ongoing supply agreement with Octapharma,
a leading, Swiss, independent, global plasma fractionation company
that specializes in human proteins. This order should be delivered
during the remainder of 2014.
This latest order relates to the purchase of PrioClear™, a
proprietary prion capture resin incorporated into Octapharma's
manufacturing process for its solvent/detergent treated plasma
product, OctaplasLG®. OctaplasLG® is currently approved for
marketing in USA and several European countries.
"We are pleased to see recurring purchase orders confirming our
growing revenue forecast for our bioseparations products. We also
anticipate demand for safer products and technologies to remain
robust in the coming years and intend to take full advantage of our
state of the art technologies to meet industry's growing demands",
said Mr. Pierre Laurin, President and Chief Executive Officer of
ProMetic Life Sciences Inc.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized
expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. ProMetic offers its state of the
art technologies for large-scale purification of biologics, drug
development, proteomics and the elimination of pathogens to a
growing base of industry leaders and uses its own affinity
technology that provides for highly efficient extraction and
purification of therapeutic proteins from human plasma in order to
develop best-in-class therapeutics and orphan drugs. ProMetic is
also active in developing its own novel small-molecule therapeutic
products targeting unmet medical needs in the field of fibrosis,
cancer and autoimmune diseases/inflammation. Headquartered in Laval
(Canada), ProMetic has R&D facilities in the UK, the U.S. and
Canada, manufacturing facilities in the UK and business development
activities in the U.S., Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about
ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, ProMetic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of ProMetic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
ProMetic's Annual Information Form for the year ended December 31,
2013, under the heading "Risk and Uncertainties related to
ProMetic's business". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation
to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other
reason, unless required by applicable securities laws and
regulations. All amounts are in Canadian dollars unless indicated
otherwise.
Pierre LaurinPresident and CEOProMetic Life Sciences
Inc.p.laurin@prometic.com+1.450.781.0115Frederic DumaisDirector,
Communications andInvestor relationsProMetic Life
Sciencesf.dumais@prometic.com+1.450.781.0115